

## MONOCLONAL ANTIBODIES (MABs) – ANTI-IL, ANTI-IgE

### PRIOR AUTHORIZATION FORM (form effective 1/3/2022)

Prior authorization guidelines for **Monoclonal Antibodies, Anti-IL, Anti-IgE** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # of pages: _____		Prescriber name:	
Name of office contact:			Specialty:		
Contact's phone number:			NPI:		State license #:
LTC facility contact/phone:			Street address:		
Beneficiary name:			Suite #:	City/state/zip:	
Beneficiary ID#:		DOB:	Phone:		Fax:

### CLINICAL INFORMATION

Drug requested:		Strength:	Dosage form (pen, vial, etc):
Dose & directions:		Quantity:	Duration: _____ months
Diagnosis:		Dx code ( <i>required</i> ):	Weight: _____ lbs / kg
Has the beneficiary used the requested medication in the past 90 days? <i>Submit documentation.</i>			<input type="checkbox"/> Yes – date of last dose: _____ <input type="checkbox"/> No
Is the requested medication being prescribed by or in consultation with a specialist?			<input type="checkbox"/> Yes <i>Submit documentation of consultation, if applicable.</i> <input type="checkbox"/> No

#### INITIAL requests

<b>For a non-preferred drug in this class:</b> Does the beneficiary have a history of trial and failure of or contraindication or intolerance to the preferred agents in this class that are approved or medically accepted for treatment of the beneficiary's condition? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred agents in this class.	<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No
--	--

**Complete all sections applicable to the beneficiary and this request. Check all that apply and SUBMIT DOCUMENTATION for each item.**

**For treatment of ASTHMA:**

Is currently receiving optimally titrated doses of, or has a contraindication or intolerance to, the following (*check all that apply*):

inhaled glucocorticoid                       long-acting beta-agonist (LABA)  
 leukotriene modifier                               other (eg, tiotropium, theophylline): \_\_\_\_\_

**For an anti-IgE MAB (eg, XOLAIR):**

Has moderate-to-severe persistent asthma induced by an unavoidable perennial allergen (pollen, mold, dust mites, etc)  
 Diagnosis confirmed by positive skin test or radioallergosorbent test (RAST)  
 Has a serum total IgE measurement between 30 international units (IU)/mL and 1300 IU/mL

**For an anti-IL MAB (eg, CINQAIR, FASENRA, NUCALA):**

Has asthma of an eosinophilic phenotype – Absolute blood eosinophil count: \_\_\_\_\_/mL    Date obtained: \_\_\_\_\_  
 Has severe asthma

**For treatment of CHRONIC SPONTANEOUS (IDIOPATHIC) URTICARIA:**

Has a history of urticaria for a period of ≥3 months  
 Requires use of steroid to control urticarial symptoms

- Has a history of trial and failure of or contraindication or intolerance to all of the following at maximal tolerated doses (*check all that apply*):
  - H<sub>1</sub> antihistamine
  - H<sub>2</sub> antihistamine
  - leukotriene modifier

**For treatment of EGPA:**

- Has a history of asthma and an absolute blood eosinophil count  $\geq 1000$ /microliter
- Has a history of asthma and a blood eosinophil level  $>10\%$  of leukocytes
- Has evidence of the following (*check all that apply*):
  - histopathological evidence of:
    - eosinophilic vasculitis
    - perivascular eosinophilic infiltration
    - eosinophil-rich granulomatous inflammation
  - neuropathy (nerve deficit or conduction abnormality)
  - pulmonary infiltrates, non-fixed
  - sino-nasal abnormality
  - cardiomyopathy
  - glomerulonephritis
  - alveolar hemorrhage
  - palpable purpura
  - positive test for ANCA
- Has a history of therapeutic failure of  $\geq 3$  months of prednisolone  $\geq 7.5$  mg/day (or equivalent) or has an intolerance or contraindication to systemic corticosteroids

**For treatment of HYPEREOSINOPHILIC SYNDROME (HES):**

- Has documented FIP1L1-PDGFR $\alpha$ -negative HES
- Has organ damage or dysfunction
- Has a blood eosinophil count  $\geq 1000$ /microliter
- Requires or has required systemic glucocorticoids to control symptoms
  - Has a contraindication or an intolerance to systemic glucocorticoids

**For treatment of nasal polyps:**

- Has a history of trial and failure of or contraindication or intolerance to nasal corticosteroids

**For an anti-IgE MAB (eg, XOLAIR):**

- Has a serum total IgE measurement between 30 international units (IU)/mL and 1500 IU/mL

**RENEWAL requests**

**Complete all sections applicable to the beneficiary and this request. Check all that apply and SUBMIT DOCUMENTATION for each item.**

**For treatment of ASTHMA:**

- Experienced measurable evidence of improvement in the severity of the asthma condition
- Will continue to use optimally titrated doses of, or has a contraindication or intolerance to, the following (*check all that apply*):
  - inhaled glucocorticoid
  - long-acting beta-agonist (LABA)
  - leukotriene modifier
  - other (eg, tiotropium, theophylline): \_\_\_\_\_

**For treatment of CHRONIC SPONTANEOUS (IDIOPATHIC) URTICARIA:**

- Experienced an improvement in symptoms
- Document rationale for continued use: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**For treatment of EGPA:**

- Experienced measurable evidence of improvement in disease activity

**For treatment of HYPEREOSINOPHILIC SYNDROME (HES):**

- Experienced measurable improvement in disease activity
- Reduced use of systemic glucocorticoids for the treatment of HES

**Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.**

**Prescriber Signature:**

**Date:**

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.